- Home
- DNP vs MIRM Comparison
DNP vs MIRM Comparison
Compare DNP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- MIRM
- Stock Information
- Founded
- DNP 1986
- MIRM 2018
- Country
- DNP United States
- MIRM United States
- Employees
- DNP N/A
- MIRM N/A
- Industry
- DNP Investment Managers
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- MIRM Health Care
- Exchange
- DNP Nasdaq
- MIRM Nasdaq
- Market Cap
- DNP 3.7B
- MIRM 3.8B
- IPO Year
- DNP N/A
- MIRM 2019
- Fundamental
- Price
- DNP $10.18
- MIRM $72.20
- Analyst Decision
- DNP
- MIRM Strong Buy
- Analyst Count
- DNP 0
- MIRM 11
- Target Price
- DNP N/A
- MIRM $79.00
- AVG Volume (30 Days)
- DNP 479.6K
- MIRM 565.3K
- Earning Date
- DNP 01-01-0001
- MIRM 11-04-2025
- Dividend Yield
- DNP 7.88%
- MIRM N/A
- EPS Growth
- DNP N/A
- MIRM N/A
- EPS
- DNP 2.30
- MIRM N/A
- Revenue
- DNP $154,887,179.00
- MIRM $429,161,000.00
- Revenue This Year
- DNP N/A
- MIRM $53.14
- Revenue Next Year
- DNP N/A
- MIRM $19.83
- P/E Ratio
- DNP $4.26
- MIRM N/A
- Revenue Growth
- DNP 3.30
- MIRM 62.33
- 52 Week Low
- DNP $8.69
- MIRM $36.88
- 52 Week High
- DNP $10.04
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- DNP 64.34
- MIRM 51.30
- Support Level
- DNP $10.12
- MIRM $68.34
- Resistance Level
- DNP $10.22
- MIRM $71.96
- Average True Range (ATR)
- DNP 0.08
- MIRM 2.50
- MACD
- DNP 0.02
- MIRM -0.29
- Stochastic Oscillator
- DNP 78.13
- MIRM 52.05
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.